Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bisphosphonates versus denosumab in postmenopausal women with osteoporosis, with and without type 2 diabetes mellitus
ChiCTR2400083259Phase 4Recruiting
- Sponsor
- Tongji Hospital, Tongji University School of Medicine
- Start
- Apr 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of alendronate, zoledronic acid and denosumab in osteoporosis (4 arms), sponsored by Tongji Hospital, Tongji University School of Medicine. Primary endpoints: Lumbar and hip bone mineral density, Drug-related adverse events and 1 more. Started Apr 2024; status: recruiting.
02
Drugs
alendronatezoledronic aciddenosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on ChiCTR2400083259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083259.